Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Cash (2018 - 2025)

Historic Change in Cash for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $41.3 million.

  • 10x Genomics' Change in Cash rose 17627.19% to $41.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $129.9 million, marking a year-over-year increase of 95364.4%. This contributed to the annual value of $129.9 million for FY2025, which is 95364.4% up from last year.
  • Per 10x Genomics' latest filing, its Change in Cash stood at $41.3 million for Q4 2025, which was up 17627.19% from $35.0 million recorded in Q3 2025.
  • Over the past 5 years, 10x Genomics' Change in Cash peaked at $112.4 million during Q1 2023, and registered a low of -$276.0 million during Q1 2022.
  • For the 5-year period, 10x Genomics' Change in Cash averaged around -$10.7 million, with its median value being -$6.2 million (2023).
  • Per our database at Business Quant, 10x Genomics' Change in Cash crashed by 90660.91% in 2022 and then surged by 104187.84% in 2025.
  • Over the past 5 years, 10x Genomics' Change in Cash (Quarter) stood at -$13.0 million in 2021, then decreased by 9.27% to -$14.2 million in 2022, then surged by 413.77% to $44.5 million in 2023, then crashed by 221.43% to -$54.1 million in 2024, then surged by 176.27% to $41.3 million in 2025.
  • Its last three reported values are $41.3 million in Q4 2025, $35.0 million for Q3 2025, and $20.7 million during Q2 2025.